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A B S T R A C T   
The cut-off values used in C6 peptide-based enzyme immunoassay (EIA), a widely used test in Lyme borreliosis 
(LB) serology, have not been thoroughly analysed. The objective of the study was to examine the performance of 
the C6 EIA, and to determine optimal cut-off values for the test. The analysed data contained results of 1368 
serum samples. C6 EIA index values were compared statistically with the immunoblot (IB) test results. The 
identified cut-off values were further tested in a well-defined LB patient cohort. Cut-off value 1.6 appeared to be 
optimal when C6 EIA was used as a stand-alone test. When using C6 EIA as the first-tier test, the optimal cut-off 
values were 0.9 and 2.4 for negative and positive results. When C6 EIA was used as a second-tier test, samples 
yielding C6 index values ≥3.0 could be considered positive. The identified cut-off values had also a high 
sensitivity to identify seropositivity among definite LB patients. The identified cut-off values refine the role of C6 
EIA in LB serology. Importantly, the use of C6 EIA leads to a reduction in the number of samples that need to be 
analysed using an IB, thus also reducing the costs. Two alternative workflows for LB serology including the C6 
EIA are suggested.   
1. Introduction 
Lyme borreliosis (LB) is a tick-borne infection caused by Borrelia 
burgdorferi (Bb) sensu lato spirochetes (borrelia) (Stanek et al., 2012). 
Borrelia serology is usually performed using the so-called two-tier 
testing approach, where the first-tier test is used to identify negative 
samples from reactive ones, and the second-tier test is used to confirm 
the results and to identify false positive samples of the first-tier test 
(Pegalajar-Jurado et al., 2018). First-tier tests are usually based on 
peptides, recombinant proteins or whole-cell sonicate preparations 
(WCS) of borrelia, and they are in many cases performed using enzyme 
immunoassay (EIA) methods. The most commonly used second-tier tests 
are immunoblots (IB). However, IB testing has several drawbacks, 
especially the subjectivity of the interpretation of the blots leading to 
occasional false-positive test results due to over-interpretation of weak 
bands on the blots. IBs are also more costly than simple EIAs, and they 
are not performed in all hospital laboratories leading to delays in 
reporting of the final results. 
The so called C6 peptide is a molecule derived from the VlsE surface 
protein of borrelia. The possibility to use C6 peptide based EIA as the 
first or the second-tier test in LB serology has been evaluated in several 
studies (Branda et al., 2011; Lipsett et al., 2016; Branda et al., 2017; 
Wormser et al., 2013; Wormser et al., 2018; Tjernberg et al., 2007). It 
has been shown to be a well-performing antigen. However, the inter-
pretation criteria used with the test have not received much consider-
ation, although there is no evidence that the criteria provided by the 
manufacturer of the most commonly used commercial C6 EIA are 
optimal, especially when we consider the different requirements for the 
test when it is used as the first or the second-tier test. Recently, it was 
demonstrated by Nigrovic and others using pooled data from five studies 
that there is a correlation between the C6 index value and the diagnosis 
of LB (Nigrovic et al., 2018). In the analysed studies, C6 EIA was used as 
the first-tier test. They further showed that higher index values associate 
with a positive result in the second tier IB analysis. Specifically, C6 index 
values ≥3.0 were suggested to indicate true LB. The authors were, 
however, unable to identify a C6 index value with such high specificity 
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that there would be no need for a confirmatory second tier IB. 
LB is a prevalent infection in Northern Europe. In Finland, the overall 
incidence of LB was estimated to be 118/100,000 population in 2014 
(Sajanti et al., 2017). The highest incidence within the country is re-
ported on the coastal areas of Finland, where the site of the present study 
(Turku University Hospital, Turku, Finland) is located. In the Clinical 
Microbiology laboratory of Turku University Hospital, LB serology is 
based on three tests: An in-house WCS EIA (used since the 1980s) which 
is performed as the first-tier screening test, C6 EIA (in use since 2012) 
which is performed as the second-tier test, and a line immunoblot (used 
in 2008–2017; currently a Luminex based multiantigen assay) which 
was performed as an additional test when the results of the WCS assay 
and the C6 EIA were inconclusive (Schulte-Spechtel et al., 2003; Schulte- 
Spechtel et al., 2004; Schulte-Spechtel et al., 2006). However, the cli-
nicians have the opportunity to request the so-called large serology 
package, which includes all these tests regardless of the individual test 
results. 
In the present study, the availability of results of the three tests from 
a large set of samples allowed us to compare the tests with each other. 
Because our primary objective was to study the performance of C6 EIA in 
relation to the IB, we used the IB result as the gold standard instead of 
comparing the C6 index values to clinical diagnoses of the patients. 
Since IgM antibody reactivity has the tendency to be unspecific, espe-
cially after four to six weeks after the infection (Steere et al., 2016; 
Dessau et al., 2018), and since we did not have detailed information of 
the infection duration of all patients, IgM results were excluded from the 
analysis. We evaluated the applicability of C6 EIA as a stand-alone test, 
as the first-tier test, or as the second-tier test, and determined the 
optimal cut-off values for the different protocols. Finally, we also tried 
out the identified cut-off values in a separate, well-defined patient 
cohort. Based on our results, we suggest two alternative protocols 
including C6 EIA for LB serology. 
2. Methods 
2.1. C6 EIA compared to RLB 
All consecutive samples sent to our laboratory for LB serology (the 
large serology package) between 2013 and 2017, and analysed at the 
time, were included in this retrospective study. Samples that had one or 
more test results missing were not included to the analysis. The serum 
samples originated both from general practice and from hospital pa-
tients (1368 samples altogether). Data obtained from the samples was 
handled anonymously and with permission (No T012/006/19) of the 
hospital district of South-Western Finland. The samples were sent to the 
laboratory at room temperature and stored at 4 ◦C until the diagnostic 
assays were performed. The large serology package includes an in-house 
WCS IgM and IgG EIA, a commercial EIA based on the C6 peptide (The 
C6 Lyme ELISA, Oxford Immunotec, Oxford, UK; previously manufac-
tured by Immunetics, Boston, USA), and the recomLine blot (RLB) 
analysis of IgM and IgG antibodies (Mikrogen GmbH, Neuried, Ger-
many). However, only IgG results were included in this study. Our in- 
house WCS assay was performed as described previously (van Beek 
et al., 2018). C6 EIA was performed and interpreted as instructed by 
manufacturer. C6 EIA resulted in C6 index value which was obtained by 
dividing the absorbance value of the sample with a standardized factor 
provided by the manufacturer. RLB was performed as instructed by the 
manufacturer. Borderline results of RLB were interpreted as positive. 
2.2. Evaluation of the identified cut-off values in patient cohort 
To evaluate how well the identified cut-off values characterize 
clinically confirmed LB cases, the identified cut-off values were tested in 
a patient cohort collected in our previous study (Kortela et al., 2020). 
The patient cohort consisted of 210 suspected Lyme neuroborreliosis 
(LNB) patients. In this previous study, 99 of these patients were 
classified as definite LNB patients with both clinical symptoms of LNB 
and laboratory confirmation of it (cerebrospinal fluid pleocytosis ≥5 
leukocytes/mm3 and intrathecal production of B. burgdorferi specific 
antibodies, or detection of B. burgdorferi DNA in the CSF). For the C6 EIA 
performance evaluation, the tabulated C6 index values were analysed in 
relation to the clinical diagnosis. The presumption was that the definite 
acute LNB patients exhibit Bb seropositivity allowing us to evaluate 
especially the sensitivity of the different cut-off values. 
2.3. Statistical analysis 
The optimal cut-off value for C6 index was determined by comparing 
the C6 EIA results to the results of RLB, which was used as the gold 
standard to identify true positives and true negatives. C6 index values 
were compared both to 1) RLB results of all samples, representing the 
situation where C6 EIA is used as a stand-alone or as the first-tier test, 
and 2) RLB results of samples that were positive in the WCS screening 
assay, representing the situation where C6 EIA is used as the second-tier 
test. The tests were compared with each other using Receiver operating 
characteristics (ROC-curve). Statistical analyses were performed with 
JMP Pro 13 (SAS institute, Cary, NC, USA). 
3. Results 
Serum samples originated from 726 (53%) women and 642 (47%) 
men. All age groups were represented among the patients with median 
age of 56 years old (Q1 = 40.15, Q3 = 68). Age range of the patients was 
from 0 to 93 years. 
3.1. C6 EIA as a stand-alone test or as the first-tier test in two-tier LB 
serology 
The comparison of the C6 EIA and RLB results of all samples repre-
sents the diagnostic set-up where C6 EIA is used as a stand-alone test, or 
alternatively, as the first-tier test in a two-tier testing protocol. In this 
comparison, the area under the curve (AUC) of the ROC-curve was 0.95 
(95% CI 0.89–0.98) (Fig. 1a). First, we examined the performance of C6 
EIA as a stand-alone test. Cut-off value 1.6 resulted in moderately high 
sensitivity (91%; 95% CI 84–95%) and specificity (89%, 95% CI 
81–94%) suggesting that 1.6 would therefore be the optimal cut-off 
value for C6 EIA as a stand-alone test in LB serology. 
Then, we evaluated C6 EIA as the first-tier test in two-tier LB 
serology. Cut-off index value 0.9 was found to be optimal to identify 
negative samples due to its high sensitivity (95%; 95% CI 89–98%) 
(Fig. 1a). The use of this cut-off resulted in a high predictive value of 
0.97 (95% CI 0.92–0.99) for IB negativity. On the other hand, the use of 
cut-off 2.4 resulted in high specificity (94%; 95% CI 88–97%), while the 
sensitivity (86%; 95% CI 78–91%) remained relatively high. The use of 
this cut-off value resulted in a predictive value of 0.86 (95% CI 
0.78–0.91) for IB positivity. With cut-off values higher than 2.4, the test 
lost sensitivity dramatically, and therefore no better cut-off value for 
identifying the positive samples could be found. In summary, the cut-off 
index value 0.9 can be used to identify negative samples, while the index 
value ≥2.4 identifies true positive samples. Samples yielding index 
values between 0.9 and 2.4 should be further analysed with a second-tier 
test. 
3.2. C6 EIA as the second-tier test in LB serology 
The performance of the C6 EIA as the second-tier test was evaluated 
using the samples that were positive in the WCS assay (n = 449) with the 
assumption that samples negative in the WCS assay are directly 
considered negative without the need to be further analysed. In the ROC 
curve analysis, the AUC was 0.86 (95% CI 0.78–0.91) (Fig. 2a). The 
optimal cut-off index value was estimated to be 3.0, which led to 
sensitivity of 88% (95% CI 80–93%) and specificity of 74% (95% CI 
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65–82%). With cut-off values ≥3.0, the test started to steeply lose its 
sensitivity, and with cut-off values <3.0, the specificity decreased 
rapidly. Importantly, this cut-off resulted in a high predictive value of 
0.95 (95% CI 0.89–0.98) for IB positivity, which is in line with the re-
quirements for a second-tier test, while the predictive value for IB 
negativity was low (0.54, 95% CI 0.44–0.63). Therefore, C6 index value 
3.0 seems to be appropriate for the identification of true antibody pos-
itive samples when C6 EIA is used as the second-tier test after a WCS EIA 
as the first-tier test. WCS EIA positive samples with C6 index values <3.0 
should be further analysed with a third-tier test. 
3.3. Testing of the identified cut-off values in a well-defined patient cohort 
We also tried out the cut-off values 1.6, 2.4 and 3.0 in a patient 
cohort collected in our previous study (Kortela et al., 2020). The median 
C6 index value of the serum samples from the 99 definite LNB patients 
was 8.3 (Q1 = 6.9, Q3 = 9.0). Index values had range of 1.2 to 10.5. Of 
the definite LNB patients, 98/99 had C6 index value ≥1.6, 96/99 had 
index value ≥2.4, and 96/99 showed index value ≥3.0. Therefore, the 
identified cut-off values had very high sensitivity in this patient cohort 
(99% (95% CI 95–100%) with cut-off 1.6, and 97% (95% CI 92–99%) 
with cut-off values 2.4 and 3.0). 
4. Discussion 
C6 EIA is a well performing and commonly used method in borrelia 
serology. However, the test could be utilized even more extensively if its 
sensitivity and specificity could be improved. Both sensitivity and 
specificity are linked to the interpretation criteria of the test, and by 
optimizing the cut-off index values used with C6 EIA for different pur-
poses, the performance of the test can be refined. The manufacturer of 
the most widely used commercial C6 EIA recommends 1.1 as the cut-off 
index value for identification of Bb positive samples, while samples with 
index values ≤0.9 are to be considered negative. However, the perfor-
mance of these cut-off values has been evaluated only in one previous 
publication (Nigrovic et al., 2018). 
The results of the present study suggest that the optimal cut-off 
values for the C6 EIA would be ≤0.9 for negative results and ≥ 2.4 for 
positive results when the assay is used as the first-tier test in LB serology. 
As can be seen in Fig. 1b, there were only 59 samples with C6 EIA index 
values ≥2.4 that were negative in the RLB assay. Thus, index values 
≥2.4 can be considered as an indication Bb seropositivity with 94% 
specificity (95% CI 88–97%). In line with this result, Nigrovic et al also 
suggested that cut-off index value 3.0 would be optimal for identifying 
true LB positive samples (Nigrovic et al., 2018). In this meta-analysis of 
4821 patients from 5 different studies, the diagnosis of the patients was 
Fig. 1. a) ROC-curve comparing C6 EIA results to RLB results of all 1368 samples. The set-up where C6 EIA is used as a stand-alone or as the first-tier test in LB 
serology is presented. Cut-off 1.6 resulted in a relatively high sensitivity (91%; 95% CI 84–95%) and specificity (89%, 95% CI 81–94%) and therefore would be 
optimal when C6 EIA is used as a stand-alone test. Cut-off 0.9 resulted in a high sensitivity (95%; 95% CI 89–98%) and PVIBN (0.97; 95% CI 0.92–0.99), and 
therefore would perform well as a cut-off value identifying borrelia antibody negative samples. The use of cut-off value 2.4, in turn, resulted in a high specificity 
(94%; 95% CI 88–97%) and PVIBP (0.86; 95% CI 0.78–0.91), and therefore could be used as a cut-off value for identifying true antibody positive samples. PVIBP =
predictive value for immunoblot positivity, PVIBN = predictive value for immunoblot negativity. b) Samples divided into categories according to cut-off values for C6 
EIA as the first-tier test in LB serology. Most of the samples with index value ≤0.9 (734/754) would be true negative when RLB is used as the gold standard. Cut-off 
value 0.9 thus has a high PVIBN. Most of the samples with index value ≥2.4 (370/429) would be true positives. Therefore, cut-off value 3.0 results in a high PVIBP. Of 
the samples with index value >0.9 and < 2.4, 143/185 would be negative and 42/185 would be positive. Therefore, these samples should be analysed with a second- 
tier test. 
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compared to C6 index values of their serum samples. While they used the 
clinical diagnosis of the patient as the gold standard, and our aim was to 
study whether the IB can be replaced with C6 EIA, both studies resulted 
in a clearly higher cut-off value than the value suggested by the manu-
facturer. On the other hand, index values ≤0.9 can be directly inter-
preted as borrelia antibody negative. The sensitivity of this cut-off is 
95% (95% CI 89–98%), and only 20 out of 754 samples with index value 
≤0.9 were RLB positive. Samples with C6 EIA index values between 0.9 
and 2.4 should, however, be further analysed with, for example, an IB 
analysis, since 23% (42/185) of the samples with index values between 
0.9 and 2.4 were RLB positive, and 77% (143/185) were negative 
(Fig. 1b). A workflow where C6 EIA is used as the first-tier test is pre-
sented in Fig. 3a. An important observation is that using this protocol of 
C6 EIA as the first-tier test, only 14% (185/1368) of the samples need to 
be analysed using two different tests. 
It has been suggested that C6 EIA could be used as a stand-alone test 
in LB serology (Lipsett et al., 2016; Wormser et al., 2013). For example, 
Pegalajar-Jurado et al (124 LB patient, including 46 patients with 
disseminated LB, 347 control samples) found that C6 EIA had 98% 
sensitivity and 95% specificity for disseminated LB when it was used as a 
stand-alone test, whereas Branda et al (169 LB patients, including 55 
patients with disseminated LB, 1300 controls) observed 87% sensitivity 
and 98% specificity (Pegalajar-Jurado et al., 2018; Branda et al., 2011). 
Lipsett et al (114 paediatric LB patients, 830 control samples) found that 
C6 EIA had 80% sensitivity and 94% specificity for LB (Lipsett et al., 
2016). However, 16 patients (14%) had an early/non-disseminated LB 
with antibodies possibly only developing at the time of sampling, which 
may have led to reduced sensitivity. In these studies, where both positive 
and equivocal results were interpreted as positive and the cut-off value 
0.9 was used, strikingly high specificities were reported. In our study, 
when C6 EIA was used as a stand-alone test, the use of cut-off value 0.9 
resulted in an acceptable sensitivity of 95%, while the specificity (78%) 
was poor. Based on our analysis, the optimal cut-off value for C6 EIA as a 
stand-alone test would be 1.6 resulting in acceptable sensitivity and 
specificity. However, with the single cut-off value 1.6, 11% (145/1368) 
of the samples would be misclassified compared to 6% (79/1368) of the 
samples when cut-off values 0.9 and 2.4 are used in the two-tier 
approach. Therefore, C6 EIA might not be optimal as a stand-alone 
test in LB serology. 
Further, our results suggest that the optimal cut-off index value is 3.0 
to identify true borrelia antibody positive samples when C6 EIA is used 
as the second-tier test after a WCS EIA as the first-tier test. The predictive 
value for IB positivity was high (0.95; 95% CI 0.89–0.98). As can be seen 
in Fig. 2b, the vast majority of the samples (334/352) testing positive in 
Fig. 2. a) ROC-curve comparing C6 EIA results to RLB results of WCS EIA positive samples, representing the set-up where C6 EIA is used as the second-tier test in LB 
serology. Cut-off value 3.0 resulted in a high PVIBP (0.95; 95% CI 0.89–0.98), and therefore can be used as a cut-off value for identifying borrelia antibody positive. 
On the other hand, the cut-off value 3.0 could not correctly categorise negative samples (PVIBN 0.54; 95% CI 0.44–0.63), and the sensitivity (88%; 95% CI 80–93%) 
and specificity (74%; 95% CI 65–82%) of this cut-off value remained low. PVIBP = predictive value for immunoblot positivity, PVIBN = predictive value for 
immunoblot negativity. b) Samples divided into categories according to WCS assay result and cut-off value 3.0 when C6 EIA would be used as the second-tier test. In 
this set-up, after the WCS EIA, 449 samples would be analysed with C6 EIA. Most samples (334/352) with C6 index ≥3.0 would be true positives. Cut-off value 3.0 
therefore has a high PVIBP. Of samples with index value <3.0, 52/97 would be true negative and 45/97 would be false negative. These samples should be analysed 
further with a third-tier test. In addition, most of the WCS assay negative samples (indicated in grey colour) would be true negative samples (866/919), while only a 
few samples would be falsely classified as negatives (53/919). 
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C6 EIA with cut-off 3.0 were also positive in RLB analysis. On the other 
hand, samples with C6 index value <3.0 should be further analysed 
using a third-tier test, e.g. an IB, due to the low predictive value for IB 
negativity (0.54; 95% CI 0.44–0.63) of the test. Of the samples with C6 
EIA result <3.0, 46% (45/97) were positive and 54% (52/97) negative 
in RLB analysis. A workflow with C6 EIA used as the second-tier test is 
presented in Fig. 3b. Importantly, however, the protocol including the 
C6 EIA as the second-tier test after the WCS EIA screening, reduces the 
number of samples that need to be analysed using an IB from 449 to 97, 
in other words by almost 80%. 
In this study, our primary aim was to investigate whether an IB can 
be replaced by the C6 EIA. Therefore, we compared the results of 
different laboratory tests head-to-head instead of comparing the test 
results against the clinical diagnosis of the patients. However, we tried 
out the identified cut-off values in a separate well-characterized patient 
cohort consisting of 210 suspected LNB patients. In this patient cohort, 
all cut-off values identified definite LNB patients with a high sensitivity. 
Thus, these cut-off values seem to be highly predictive for clinically 
diagnosed LNB. One could presume, that these results can be extended to 
concern also other forms of disseminated LB. 
There are some limitations in our study. First, there might be a bias 
caused by the fact that our data originates from patient samples of which 
the large serology package including the three tests was requested. The 
patients may have had more severe or apparent symptoms, which in turn 
would have prompted the clinicians to request the large serology 
package. At the same time, the samples included in this study can be 
considered as a strength. By including samples from both general 
practice and hospital patients in the analysed material, many different 
types of patients were represented. Thus, the identified cut-off values 
can be applied in laboratories that perform LB diagnostics for both 
primary health care units and hospitals. 
Second, the cut-off values that we have determined might not be 
optimal in other areas of the world. The optimal cut-off values most 
likely should be determined locally. Our material consisted of samples 
collected from Finnish patients. In Finland, the proportion of borrelia 
genospecies (B. afzelii as the most abundant and B. garinii as the second 
most abundant genospecies) is very similar to most of the other regions 
in Europe (Laaksonen et al., 2017). Therefore, the cut-off values we 
determined could be used in Europe, while different values may need to 
be defined for samples of US patients. However, Nigrovic and others 
from the US ended up with a very similar result. This suggests that 
similar cut-off values might be utilized both in Europe and in North 
America. 
Third, the WCS based EIA used in this study is an in-house assay. 
However, the WCS assay is based on B. burgdorferi s.s. B31-strain, which 
is used also in commercial assays as the source of the antigen. In addi-
tion, we calculated that the sensitivity of our WCS EIA was 88% (95% CI 
80–93%) and specificity was 93% (95% CI 86–97%) when RLB was used 
as the gold standard (379 true positive, 866 true negative, 70 false 
positive and 53 false negative results). Therefore, our results concerning 
C6 EIA cut-off values when the test is used as the second-tier test in LB 
serology are exploitable with any first-tier test with similar performance. 
5. Conclusions 
In conclusion, when C6 EIA is used as the first-tier test, samples with 
index values ≤0.9 should be considered negative, and samples with C6 
index values ≥2.4 can be interpreted to be borrelia antibody positive 
(Fig. 3a). Samples with C6 index values between 0.9 and 2.4 should be 
further analysed with a second-tier test. According to our data, the cut- 
off 3.0 seems to perform well as a cut-off C6 index value for positivity, 
when the test is used as the second-tier test. In this set-up, samples 
yielding index values <3.0 should be further analysed with third-tier 
test like a line immunoblot, bead immunoassay, or Western blot 
(Fig. 3b). Importantly, both proposed workflows would significantly 
reduce the number of samples that would need to be analysed with an IB 
or a similar, usually more costly, assay. Since C6 EIA is easy to be per-
formed without the requirement of subjective IB signal intensity inter-
pretation, the incorporation of the assays into the LB serology protocol is 
worth consideration. 
Glossary 
Enzyme immunoassay (EIA) can be used to detect antibodies in 
serum samples. An antigen conjugated to enzyme binds to the antibody 
in the sample and the enzyme converts the added substrate into a 
detectable substance. 
Immunoblot (IB) has pathogen antigens bound on their surface in a 
specific order. The antibodies in the sample bind to the antigens and can 
then be detected and identified according to the position of band in the 
immunoblot. 
Fig. 3. Proposed workflows for LB serology using C6 EIA. a) When C6 EIA is used as the first-tier test, C6 index values can be divided into three categories: index 
values ≥2.4 indicate Bb seropositivity, index values ≤0.9 indicate negative result, and index values between 0.9 and 3.0 are equivocal results. Samples yielding 
equivocal results should be further analysed with a second-tier test. b) When C6 EIA is used as a second-tier test, index values ≥3.0 indicate Bb seropositivity, while 
samples with index values <3.0 should be analysed further with a third-tier test (e.g. an IB). 
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draft; Annukka Pietikäinen: data curation, formal analysis, writing- 
review and editing; Elisa Kortela: data curation, formal analysis; Mari 
J. Kanerva: data curation, formal analysis; Jarmo Oksi: data curation, 
formal analysis; Jukka Hytönen: conceptualization, data curation, 
formal analysis, supervision, writing-review and editing. All authors 
read and approved the final manuscript. 
Declaration of Competing Interest 
J.H. is a part time consultant for the diagnostic company Reagena 
(Toivala, Finland). E.K. reports a non-financial support from MSD, 
outside the submitted work. The other authors report no conflicts of 
interest. 
Acknowledgements 
Tuula Rantasalo is acknowledged for excellent technical assistance 
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